Evidence map›Paper›PMID 41390649›Full record

ArticleJournal of nanobiotechnology2025

Diselenide-bridged hybrid mesoporous silica for radiosensitization and radioprotection in the radioimmunotherapy of colorectal cancer.

Fan Zhang, Xiaochun Xie, Junna Lu, Hui Fang, Quanxing Ning, Jiayi Wang, Yige Shan, Shaowen Wang, Xin Zhao, Fangman Chen and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Fan Zhang *Department of Biomaterials and Stem CellsSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science (CAS), Suzhou, 215163, China.
Xiaochun Xie *School of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Junna Lu *School of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Hui FangSchool of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Quanxing NingSchool of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Jiayi WangSchool of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.
Yige ShanSchool of Pharmacy, Xuzhou Medical University, Xuzhou, 221004, China.
Shaowen WangSchool of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Xin ZhaoSchool of Medicine, South China University of Technology, Guangzhou, 510006, Guangdong, China.
Fangman ChenState Key Laboratory of Quality Research in Chinese MedicineInstitute of Chinese Medical Sciences, University of Macau, Macau, 999078, China. chenfangman@hotmail.com.
Wenfei DongDepartment of Biomaterials and Stem CellsSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science (CAS), Suzhou, 215163, China.
Zhimin ChangDepartment of Biomaterials and Stem CellsSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science (CAS), Suzhou, 215163, China. changzm@sibet.ac.cn.
Li LiDepartment of Biomaterials and Stem CellsSuzhou Institute of Biomedical Engineering and Technology, Chinese Academy of Science (CAS), Suzhou, 215163, China. lil@sibet.ac.cn.

Funding

China Postdoctoral Science Foundation funded project 2021M702414the National Key R&D Program of China 2022YFC2403500the National Natural Science Foundation of China 82172077the Natural Science Foundation of Shandong Province, China ZR2022QB243the Youth Innovation Promotion Association of CAS 2022326
6 · The paper itself

Abstract

Radioimmunotherapy has been recognized as a promising strategy for the treatment of colorectal cancer; however, it faces several challenges, including limited efficacy, weak immune activation, and severe radiation-induced colitis. To address these issues, we developed hollow mesoporous silica nanoparticles (

Indexed as

Colorectal NeoplasmsRadiation-Protective AgentsRadiation-Sensitizing AgentsRadioimmunotherapySilicon DioxideAnimalsCell Line, TumorHumansMiceMice, Inbred BALB CNanoparticlesPorosityReactive Oxygen SpeciesRadiation-Protective AgentsRadiation-Sensitizing AgentsReactive Oxygen SpeciesSilicon DioxideColorectal cancerDi-selenideRadiation colitisRadioimmunotherapyRedox

Identifiers

PMID41390649
PMCPMC12821053

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.